EUVIMEDObjevte EUVIMED
FallberichtOpen access

Potential role of tirzepatide, a dual GLP ‐1 and GIP receptor agonist, for preventive treatment of migraine: A case series

Tulsi Shah, Carrie Dougherty, Jessica Ailani, Thomas Kerrigan

Headache: The Journal of Head and Face Pain · 2026-09 · 66 (8) · 1916-1919

DOI: 10.1111/head.70152 ↗

At a glance

Fallbericht in Headache: The Journal of Head and Face Pain, published online on 2026-07-06. Written by Tulsi Shah and 3 co-authors. Institution: Capital Neurology and Sleep Medicine, McLean, Virginia, USA. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Migraine Disorders, Receptors, Gastrointestinal Hormone, Tirzepatide. Cited 3 times so far (Crossref); 16 references. The full text is freely available in PubMed Central.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Obesity is a known comorbidity of migraine that can increase attack frequency and severity and lead to disease chronification. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and related medications have demonstrated benefits beyond glycemic control and weight management, with emerging evidence suggesting a potential role in pain modulation. Clinical observations have also suggested the role of GLP‐1 based therapies for the treatment of idiopathic intracranial hypertension, but their role in migraine has not been established. Case Series Here, we report two cases of patients with migraine who experienced a reduction in migraine headache frequency following initiation of tirzepatide, a dual GLP‐1 and glucose‐dependent insulinotropic polypeptide receptor agonist.

Discussion

These cases suggest that GLP‐1 receptor agonists and dual GLP‐1 and glucose‐dependent insulinotropic polypeptide receptor agonists may have potential therapeutic relevance in migraine management. Notably, both patients experienced weight loss with treatment, which represents a significant confounding factor that limits conclusions about a direct migraine‐specific effect. These cases should be interpreted as preliminary observations. Future studies evaluating migraine outcomes in patients treated with these medications are needed to better understand the underlying mechanism and explore their potential role as novel therapeutic pathways for migraine.

Subjects

MeSH terms (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsMigraine DisordersReceptors, Gastrointestinal HormoneTirzepatideFemaleHumansMiddle AgedObesity

Author keywords

glucagon‐like peptide‐1glucose‐dependent insulinotropic polypeptidemigrainemigraine preventionobesitytirzepatide

Substances

gastric inhibitory polypeptide receptorGlucagon-Like Peptide-1 Receptor AgonistsReceptors, Gastrointestinal HormoneTirzepatide

Authors and institutions

  • Capital Neurology and Sleep Medicine, McLean, Virginia, USA.
  • Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA.
  • Virtua Neurosciences, Marlton, New Jersey, USA.

Cite

APA

Shah, T., Dougherty, C., Ailani, J., & Kerrigan, T. (2026). Potential role of tirzepatide, a dual GLP ‐1 and GIP receptor agonist, for preventive treatment of migraine: A case series. Headache: The Journal of Head and Face Pain, 66(8), 1916-1919. https://doi.org/10.1111/head.70152

Vancouver

Shah T, Dougherty C, Ailani J, Kerrigan T. Potential role of tirzepatide, a dual GLP ‐1 and GIP receptor agonist, for preventive treatment of migraine: A case series. Headache: The Journal of Head and Face Pain. 2026;66(8):1916-1919. doi:10.1111/head.70152

BibTeX
@article{Shah2026,
  author = {Shah, Tulsi and Dougherty, Carrie and Ailani, Jessica and Kerrigan, Thomas},
  title = {Potential role of tirzepatide, a dual GLP ‐1 and GIP receptor agonist, for preventive treatment of migraine: A case series},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {8},
  pages = {1916--1919},
  doi = {10.1111/head.70152}
}
Start for free →